שווי כולל של החברה: Longeveron Inc. (LGVN)

Longeveron Inc. (LGVN) is developing Lomecel-B to combat dementia and age-related changes, leveraging a robust foundation of scientific research. This chart on the GURU.Markets platform, where the indicator is fixed at -3.98, visualizes this process. The business also focuses on therapies for chronic pathologies with sustained demand, although the clinical trial stage and the maintenance of cryocenters currently increase unit costs.

The stable operation of the Longeveron Inc. biomanufacturing complex establishes the material foundation that reflects the company's enterprise value (EV). This indicator determines the total buyout price of the business, excluding market noise. The calculation is based on the sum of market capitalization and liabilities minus cash and cash equivalents. The trend in enterprise value (EV) allows for an assessment of the real value of assets, helping investors avoid overpayment or bankruptcy risks.